ArticlePathology oncology research : POR2021
Comprehensive Analysis of the Expression and Prognosis for Laminin Genes in Ovarian Cancer.
Article in Pathology oncology research : POR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Molecular plasticity of LAMA3 across the disease spectrum: pathogenic mechanisms and clinical translation.Histochemistry and cell biology · 2026Pooled it
- LAMC2 as a prognostic biomarker in human cancer: a systematic review and meta-analysis.BMJ open · 2022Pooled it
- Proteomic analysis of malignant ascites and its impact on ovarian cancer spheroids.Clinical proteomics · 2026Article
- A machine learning-based basement membrane gene signature model for predicting ovarian cancer survival.Translational cancer research · 2026Article
- Low LAMA2 expression may affect drug resistance and prognosis in ovarian cancer via positive LGR5 coexpression.Translational cancer research · 2026Article
- LAMA1 Promotes Tumor-Associated Macrophages Polarization Towards the M2 Phenotype and Induces Colorectal Cancer.Applied biochemistry and biotechnology · 2026Article
- Deciphering brain metastasis in epithelial ovarian cancer: multimodal analysis and potential biomarkers.NPJ precision oncology · 2026Article
- The uterine secretome initiates growth of gynecologic tissues in ectopic locations: re-evaluating the evidence.Pathology oncology research : POR · 2026Review
- Development of a novel prognostic model based on laminin α5, associated with immune infiltration and therapeutic response in ovarian cancer utilizing online resources.European journal of medical research · 2025Article
- A Comprehensive Multiomics Signature of Doxorubicin-Induced Cellular Senescence in the Postmenopausal Human Ovary.Aging cell · 2025Article
- The role of LAMA5 in breast cancer progression and its potential in immunotherapy.Discover oncology · 2025Article
- Cancer therapy via neoepitope-specific monoclonal antibody cocktails.Cancer immunology, immunotherapy : CII · 2025Article
- Nutritional ketosis modulates the methylation of cancer-related genes in patients with obesity and in breast cancer cells.Journal of physiology and biochemistry · 2025Article
- Laminin α5: a key factor in tumor metastasis.Clinical & experimental metastasis · 2025Review
- Biological implications of decoding the extracellular matrix of vulva cancer.Oncology reports · 2025Review
- Identification of novel variants underlying non-syndromic primary ovarian insufficiency using a targeted NGS gene panel.Frontiers in endocrinology · 2025Article
- Expression Profiling of Coding and Noncoding RNAs in the Endometrium of Patients with Endometriosis.International journal of molecular sciences · 2024Article
- TOB1 inhibits the gastric cancer progression by focal adhesion pathway and ERK pathway based on transcriptional and metabolic sequencing.BMC cancer · 2024Article
- Alterations of Matrisome Gene Expression in Naturally Aged and Photoaged Human Skin In Vivo.Biomolecules · 2024Article
- Proteomic analysis of exosomes secreted during the epithelial-mesenchymal transition and potential biomarkers of mesenchymal high-grade serous ovarian carcinoma.Journal of ovarian research · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Survival is low in ovarian cancer (OC). Most OC patients demonstrate advanced metastases, and recurrence is common. Dysregulation of laminin interactions is associated with cancer development. However, it is unknown whether laminin subunits can be considered as biomarkers for OC diagnosis, prognosis, and treatment. We used cBioPortal, GEO, ONCOMINE, GEPIA, Human Protein Atlas, Kaplan-Meier Plotter, TIMER, and Metascape to determine the associations among laminin expression, prognosis, and immune cell infiltration in OC. LAMA5, LAMB3, and LAMC2 mRNAs and LAMA3, LAMB1/B2/B3, and LAMC1/C2 proteins were overexpressed in OC tissues compared with normal ovaries. LAMA4, LAMB1, and LAMC1 mRNA upregulation was positively correlated with worse overall survival (OS) and progression-free survival (PFS) in OC. Elevated LAMA2 and LAMC2 mRNA expression levels were related to better PFS or OS, respectively. The results speculated that LAMA5 could potentially be a good prognostic factor in OC. Its expression proves valuable for predicting OS in patients diagnosed with stage Ⅳ and grade 3 OC and PFS in patients diagnosed with all OC stages or grades. LAMB3 and LAMC2 expression was correlated with platinum resistance development. ROC analysis of laminins in OC sets revealed that LAMA2/A4/A5, LAMB1/B2/B3, and LAMC2 could be used to differentiate between malignant tumors and non-neoplastic tissues. LAMA1/A5 and LAMC1 were significantly and negatively correlated with various tumor immune infiltrates (TILs), especially with dendritic cells, CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.